首页膀胱肿瘤治疗及预后证据详情

Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis

原文: 2023 年 发布于 Anticancer Drugs 15 卷 第 1 期 4-14 浏览量:211次

作者: Wang L. Shi G. Zhao G. He W. Cen Z. Xu F.

作者单位: a Department of Environmental Health, Faculty of Health Sciences , American University of Beirut , Beirut , Lebanon. b Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine , American University of Beirut , Beirut , Lebanon. c Faculty of Medicine , Clinical Research Institute, American University of Beirut , Beirut , Lebanon.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.14715/cmb/2019.65.7.2

关键词: Humans *Adjuvants Immunologic/therapeutic use/adverse effects Administration Intravesical Neoplasm Recurrence Local/epidemiology *Urinary Bladder Neoplasms/pathology Drug Administration Schedule Bcg Cvnmi Desabastecimiento Dosis completa Dosis reducida Full dose Nmibc Reduced dose Shortage

文献简介

This study aimed to investigate whether Enfortumab vedotin (EV) is suitable for patients with locally advanced or metastatic urothelial carcinoma and to perform a meta-analysis of its efficacy and safety. Five studies involved 584 patients were included in the meta-analysis. The results of single-arm meta-analysis showed that with EV at 1.25 mg/kg, the objective response rate (ORR) was 47%. The meta-analysis indicated that EV showed good efficacy and safety in the patient population of locally advanced or metastatic urothelial carcinoma.

热门文献